trending Market Intelligence /marketintelligence/en/news-insights/trending/dcoNhpPtfphfIKR-5SkPgg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Mallinckrodt upgraded by S&P following debt exchange; outlook negative

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Mallinckrodt upgraded by S&P following debt exchange; outlook negative

S&P Global Ratings upgraded Mallinckrodt PLC's long-term issuer credit rating to CCC from SD following the specialty pharmaceutical company's recent debt exchange.

Mallinckrodt exchanged $706 million of various unsecured notes for $323 million worth of new 10% second-lien notes due 2025. This reduced overall debt principal by about $383 million.

The rating agency viewed the U.K.-based drugmaker's exchange offers as distressed exchanges, as the lenders were expected to receive a lesser amount than promised when the transaction closes.

Ratings said there is a higher probability of another distressed exchange by the company in 2020 as it has over $600 million of debt maturing in April 2020, plus risk from a possible settlement in the ongoing opioid litigation. The outlook on the ratings is therefore negative.

Ratings believes that even though Mallinckrodt continues to generate positive free cash flow, the company's ability to access the capital markets to refinance its maturing debt is limited due to the opioid liabilities.

The drugmaker's shares were up by almost 6.55% to $3.58 as of 11:55 a.m. ET on Dec. 12.

This S&P Global Market Intelligence news article may contain information about credit ratings issued by S&P Global Ratings. Descriptions in this news article were not prepared by S&P Global Ratings.